Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Shunkai Zhou"'
Autor:
Tingting Zhang, Chao Meng, Wei He, Tao Xu, Yi Yang, Chongqi Tu, Ling Zhang, Xiaofeng Sun, Chunrong Zhu, Xueyi Dang, Ke Wang, Chuan Chen, Xiong Yan, Huiting Xu, Le Huang, Enlai Jiang, Feng Xia, Xinming Zhou, Shunkai Zhou, Weidong Zang, Xifeng Li, Jin Zhang, Jiaping Zheng, Jianjun Xin, Bin Huang, Guopei Zhu, Jiexiang Zhu, Jun Liang
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Data on long-term cancer survivors treated with apatinib are lacking. This study aimed to describe the characteristics of long-term cancer survivors after apatinib-based therapy, and to know about their satisfaction degree with ap
Externí odkaz:
https://doaj.org/article/20f039f7b7e74a27bbfeddfa4061b205
Autor:
Jingjing Duan, Yongwei Xie, Lijuan Qu, Lingxiong Wang, Shunkai Zhou, Yu Wang, Zhongyi Fan, Shengsheng Yang, Shunchang Jiao
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-15 (2018)
Abstract Background Immunoscore, as a prognostic tool defined to quantify in situ immune cell infiltrates, appears to be superior to the TNM staging system. In esophageal squamous cell carcinoma (ESCC), no immunoscore has been established; however, i
Externí odkaz:
https://doaj.org/article/077cd3d36c314fb69a9cbd31047b36e9
Autor:
Shunkai Zhou, Dehua Zeng, Meiqing Zhang, Mengmeng Chen, Yaming Liu, Qiqiang Chen, Zhenya Lin, Shengsheng Yang, Zhichao Fu, Wenmin Ying, Duohuang Lian
Background: Lung adenocarcinoma (LUAD) has a complex tumor heterogeneity. This study aimed to identify LUAD subtypes and build a reliable prognostic signature based on the activity changes of the hallmark and immunologic gene sets. Methods: Changes i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c79d95835d0abff7c2569d0b30cb4d17
https://doi.org/10.21203/rs.3.rs-2248895/v1
https://doi.org/10.21203/rs.3.rs-2248895/v1
Autor:
Duohuang, Lian, Luoyu, Lian, Dehua, Zeng, Meiqing, Zhang, Mengmeng, Chen, Yaming, Liu, Wenmin, Ying, Shunkai, Zhou
Publikováno v:
Medicine. 101:e32045
Abnormal DNA methylation can regulate carcinogenesis in lung adenocarcinoma (LUAD), while transcription factors (TFs) mediate methylation in a site-specific manner to affect downstream transcriptional regulation and tumor progression. Therefore, this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48c717ace88f3f05af3bf26fb33c0611
https://doi.org/10.1097/md.0000000000032045
https://doi.org/10.1097/md.0000000000032045
Publikováno v:
Neural Information Processing ISBN: 9783030921842
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c3a985261d302ff28566f1bd723f12d
https://doi.org/10.1007/978-3-030-92185-9_15
https://doi.org/10.1007/978-3-030-92185-9_15
Publikováno v:
Clinical and experimental pharmacologyphysiologyREFERENCES. 47(9)
Non-small cell lung cancer (NSCLC) has been considered to be the most common category of lung cancer, comprising approximately 80% of lung cancers. Long non-coding RNAs (lncRNAs) were diffusely documented to modulate carcinogenesis or progression of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::482f4794416bd7e002631889366c086d
https://pubmed.ncbi.nlm.nih.gov/32298476
https://pubmed.ncbi.nlm.nih.gov/32298476
Publikováno v:
Medicine. 99:e21965
BACKGROUND The epidermal growth factor receptor (EGFR) mutation status related to the treatment approach for advanced non-small cell lung cancer (NSCLC) patients. This study aimed to evaluate the diagnostic accuracy of peripheral blood circulating tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c72ba330d90785b3cd0c541e68f41b15
https://doi.org/10.1097/md.0000000000021965
https://doi.org/10.1097/md.0000000000021965
Autor:
Shunkai Zhou, Lingxiong Wang, Lijuan Qu, Yongwei Xie, Shunchang Jiao, Jingjing Duan, Shengsheng Yang, Yu Wang, Zhongyi Fan
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-15 (2018)
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-15 (2018)
Background Immunoscore, as a prognostic tool defined to quantify in situ immune cell infiltrates, appears to be superior to the TNM staging system. In esophageal squamous cell carcinoma (ESCC), no immunoscore has been established; however, in situ tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9536f5c161ff97399c107d6fee68cc2
https://doi.org/10.1186/s40425-018-0418-7
https://doi.org/10.1186/s40425-018-0418-7
Autor:
Jingjing Duan, Yongwei Xie, Lijuan Qu, Lingxiong Wang, Shunkai Zhou, Wang, Yu, Zhongyi Fan, Shengsheng Yang, Shunchang Jiao
Table S1. Primary antibodies used in IHC/IF. (PDF 81 kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c003fb9d936147b86d39e3797272d29
Autor:
Jingjing Duan, Yongwei Xie, Lijuan Qu, Lingxiong Wang, Shunkai Zhou, Wang, Yu, Zhongyi Fan, Shengsheng Yang, Shunchang Jiao
Figure S1. Representative IHC images of CD8, CD4, Foxp3, CD33, PD-1, PD-L1, TIM3, LAG3, OX-40, ICOS and IDO1 staining in esophageal squamous cell carcinoma samples (Ă 200). TC, tumor cell; IC, immune cell. (PDF 416 kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83298d11d96f13f7b9b9168b05e0accd